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Abstract
Introduction: Targeted biopsy of tumour-suspicious le-
sions detected in multiparametric magnetic resonance im-
aging (mpMRI) plays an increasing role in the active surveil-
lance (AS) of patients with low-risk prostate cancer (PCa). 
The aim of this study was to compare MRI/ultrasound-fu-
sion biopsy (fusPbx) with systematic biopsy (sysPbx) in pa-
tients undergoing biopsy for AS. Methods: Patients under-
going mpMRI and transperineal fusPbx combined with 
transrectal sysPbx (comPbx) as surveillance biopsy were in-
vestigated. The detection of Gleason score upgrading and 
reclassification according to Prostate Cancer Research In-
ternational Active Surveillance criteria were evaluated. Re-
sults: Eighty-three patients were enrolled. PCa upgrading 
was detected in 39% by fusPbx and in 37% by sysPbx (p = 
1.0). The percentage of patients who were reclassified in 
fusPbx and sysPbx (p = 0.45) were 64 and 59% respectively. 
ComPbx detected more frequently tumour upgrading than 
fusPbx (71 vs. 64%, p = 0.016) and sysPbx (71 vs. 59%, p < 
0.001) and more patients had to be reclassified after comP-
bx than after fusPbx or sysPbx alone. Conclusions: The com-
bination of fusPbx and sysPbx outperforms both modalities 
alone with regard to the detection of upgrading and reclas-
sification in patients under AS. Because a high missing rate 
of significant PCa still exists in both biopsy modalities, a 
combination of fusPbx and sysPbx should be recommend-
ed in these patients. © 2018 S. Karger AG, Basel
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Introduction
Active surveillance (AS) has been widely accepted as a 
treatment strategy in patients with low-risk prostate cancer 
(PCa) [1–3]. It intends to reduce overtreatment and to de-
fer treatment by surgery or radiotherapy until the time of 
progression. However, definitions of AS criteria are still 
heterogeneous and long-term follow-up data are pending 
[2]. Moreover, the rate of reclassification with consecutive 
conversion to active treatment in surveillance biopsy dur-
ing the follow-up is considerable [4]. In the Prostate Can-
cer Research International Active Surveillance (PRIAS) 
study, 28% of patients were reclassified at surveillance bi-
opsy after a median follow-up of 1.6 years [1]. Therefore, 
detection and accurate assessment of tumour aggressive-
ness are essential to correctly identify patients with low-
risk PCa and to avoid misclassification and potentially 
harmful postponement of active treatment. 
Multiparametric magnetic resonance imaging (mpM-
RI) of the prostate enables better tumour visualization and 
therefore has become an important method for diagnosing 
PCa using targeted biopsy [5–9]. Targeted biopsy like MRI-
ultrasound-fusion biopsy (fusPbx) has a higher detection 
rate especially for high-grade PCa compared to convention-
al random biopsy [6, 7, 9]. Previous studies have reported a 
better prediction in tumour aggressiveness in the primary 
biopsy and a lower rate of tumour reclassification in the fol-
low-up in patients with low-risk PCa if the initial biopsy was 
performed by the combination with fusPbx [10, 11]. Fur-
thermore, it has been shown that mpMRI and consecutive 
targeted biopsy during AS protocols enhance the identifica-
tion of AS patients requiring definitive treatment [12]. Thus, 
mpMRI combined with fusPbx presents a promising meth-
od for surveillance biopsy in patients undergoing AS. As a 
consequence, contemporary guidelines recommend mpM-
RI in patients with low-risk PCa before AS [13, 14].
The aim of this study was to evaluate the value of mpM-
RI and transperineal fusPbx in patients with low-risk PCa 
undergoing surveillance biopsy in an AS protocol com-
pared to transrectal systematic prostate biopsy (sysPbx) and 
to the combination of both biopsy modalities (comPbx).
Patients and Methods
Recruitment
In this retrospective diagnostic study, patients with proven low-
risk PCa undergoing surveillance biopsy in the frame of an AS pro-
tocol were enrolled. This study was approved by the Institutional 
Review Board of the Technical University of Dresden (Vote: 
EK53022014).
For the surveillance biopsy, all patients underwent transperi-
neal fusPbx combined with transrectal sysPbx.
Primary endpoints were the proportion of patients diagnosed 
with histological tumour progression defined as the evidence of 
PCa with Gleason patterns of 4–5 and the proportion of reclassifi-
cation to clinically significant PCa according to PRIAS criteria in 
at least one biopsy modality. Criteria for clinically insignificant 
PCa according to PRIAS were ≤cT2c, ≤2 cores with proven cancer, 
Gleason score ≤6 (3 + 3), prostate specific antigen (PSA) density 
<0.2 ng/mL2 and PSA <10 ng/mL.
MRI Investigations
Patients underwent mpMRI at the department of Radiology at 
University Hospital Dresden or in ambulatory radiology offices. 
At the department of Radiology, mpMRI of the prostate were per-
formed on a 3 Tesla MR system (Magnetom Verio, Siemens Med-
ical Solutions, Erlangen, Germany) without endorectal-coil. The 
mpMRI protocol included T2-weighted images in transverse and 
coronal orientation, T1-weighted images, diffusion-weighted im-
ages, dynamic contrast-enhanced imaging and contrast-enhanced 
T1-weighted images with fat suppression in transverse orientation. 
Total MRI acquisition time was 25 min. MpMRIs performed in 
ambulatory radiology offices were included in further analysis, if 
at least 2 MRI sequences were available. 
The evaluation of the mpMRI was performed by uro-radiolo-
gists with an experience of >15 years in evaluating prostate MRI. 
The prostate imaging and data system (PI-RADS) v1 and v2 
classifications based on criteria of the European Society of Uro-
genital Radiology [15–17] were used to evaluate tumour-suspi-
cious lesions. The definition of lesions in PI-RADS v1 and v2 was 
as follows: PI-RADS 1: very low (clinically significant PCa is high-
ly unlikely); PI-RADS 2: low (clinically significant PCa is unlike-
ly); PI-RADS 3: intermediate (clinically significant PCa is equivo-
cal); PI-RADS 4: high (clinically significant PCa is likely); PI-
RADS 5: very high (clinically significant PCa is highly likely). 
When mpMRI was performed in ambulatory radiology offices, 
the mpMRI was re-evaluated by the in-house radiologists. The 
maximum PI-RADS (maxPI-RADS) in mpMRI was defined as 
the lesion with the highest PI-RADS of all lesions per patient. The 
influence of the maxPI-RADS for the biopsy results in fusPbx, 
sysPbx and in the combination of both was investigated. Further-
more, all lesions detected in mpMRI were evaluated regarding the 
tumour detection rate and Gleason Score (GS). Lesions classified 
as PI-RADS 2 and PI-RADS 3 were evaluated for tumour detec-
tion, if these lesions existed alone or beside other lesions classified 
with a higher PI-RADS.
Prostate Biopsy
The BioJet-System (Fa. d&k technologies, Barum, Germany) 
was used for transperineal fusPbx. The combination of transperi-
neal fusPbx and transrectal sysPbx was performed as previously 
described [18]. Targeted biopsy was performed via a transperineal 
approach while taking at least 2 cores per lesion depending on the 
size of the lesion. Lesions classified as PI-RADS ≥2 were biopsied. 
Subsequently in the same session, every patient underwent a 12-
core sysPbx transrectally. In sysPbx, the needle was placed accord-
ing to a scheme covering 12 regions of the prostate (medial and 
lateral apex, medial and lateral mid prostate and medial and lat-
eral base in both lobes). SysPbx was completed by the same urolo-
gist who had performed the targeted biopsy. 
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All biopsy specimens were investigated at the Department of 
Pathology of the University Hospital Dresden. The biopsy cores 
were paraffin embedded. Five step sections were cut at 2 µm and 
stained with haematoxylin-eosin and microscopically examined. 
We defined a GS ≥7 (3 + 4) as significant PCa. 
Analysis of detection rates in lesions detected in mpMRI was 
performed based on patient characteristics (maxPI-RADS) and on 
lesion characteristics; this analysis includes the analysis of all le-
sions detected by mpMRI.
Statistical Analysis
Data were analysed using SPSS version 23.0 (IBM Corp., Ar-
monk, NY, USA). Categorical variables were presented by absolute 
and relative frequencies. Continuous variables were described by 
means, complemented by median and range. Student t test and χ2 
test were applied to determine differences between numerical and 
categorical variables. The McNemar-test was used to compare the 
detection rate of fusPbx to sysPbx and comPbx. A p value of <0.05 
was considered statistically significant. Uni- and multivariate lo-
gistic regression analyses were used to evaluate the reclassification 
to clinically significant PCa according to PRIAS criteria.
Results
Detection and Reclassification Rates in MRI/
Ultrasound-Fusion Biopsy and Systematic Biopsy
Eighty-three patients with low-risk PCa undergoing sur-
veillance biopsy by fusPbx in combination with sysPbx were 
included. Low-risk PCa was diagnosed either by sysPbx 
alone (n = 69) or by fusPbx in combination with sysPbx (n = 
14). Patients’ characteristics are depicted in Table 1.
Table 1. Patients’ demographics (n = 83), findings on mpMRI and histopathology of prostate biopsy cores
Parameter Value 
Age, years, median (IQR) 67 (63–72)
PSA, ng/mL, median (IQR) 6.9 (5.5–9.3)
Suspicious findings in DRE, n (%) 6 (7.2)
Prostate volume, mL, median (IQR) 44 (32–63)
PSA density, ng/mL2, median (IQR) 0.12 (0.05–0.25)
Overall biopsy cores per patient, n, median (IQR) 18 (16–21)
Targeted biopsy cores per patient, n, median (IQR) 6 (4–8)
Systematic biopsy cores per patient, n, median (IQR) 12 (12–12)
Ratio of positive cores to total cores in targeted biopsy per patient, %, mean ± SEM 29±4
Cancer core involvement in targeted biopsy, mm, mean ± SD 3.7±3.5
Ratio of positive cores to total cores in systematic biopsy per patient, %, mean ± SEM 18±2
Cancer core involvement in systematic biopsy, mm, mean ± SD 1.9±1.6
Number of lesions/patient, n, median (IQR) 1 (1–2)
MRI (n) before prostate biopsy
Total number of lesions
Number of lesions evaluated according to PI-RADS
PI-RADS of lesion, n
2
3
4
5
153
114
21
37
33
23
PI-RADSmax in investigated patients, n
No PI-RADS indicated
2
3
4
5
31
4
20
15
13
Histological findings (n) in combined prostate biopsy
Gleason Score of biopsy (combination of targeted and systematic biopsy, n
No tumour
3 + 3 = 6
3 + 4 = 7
4 + 3 = 7
≥8
18
25
26
7
7
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In the combination of both biopsy modalities, PCa de-
tection rate was 78% (65/83), whereby tumour progres-
sion to a GS ≥7 (3 + 4) was detected in 48% (40/83). Re-
classification according to PRIAS criteria occurred in 
71% (59/83) of patients. SysPbx detected more PCa of 
any Gleason grade than fusPbx (63% [52/83] vs. 55% 
(46/83); p = 0.377). FusPbx detected progression to clin-
ically significant PCa (GS ≥7 [3 + 4]) as frequently as sys-
Pbx (39% [32/83] vs. 37% [31/83]; p = 1.0). In fusPbx 
alone, 64% (53/83) would be reclassified according to 
PRIAS criteria compared to 59% (49/83) in sysPbx alone 
(p = 0.454).
Regarding missing rates, fusPbx alone would have 
missed 23% of significant PCa (9/40), whereas sysPbx 
alone would have missed 25% of significant PCa (10/40; 
Table 2). 
The combination of both biopsy modalities found 
more frequently PCa than fusPbx (78% [65/83] vs. 55% 
[46/83], p < 0.005) and more than sysPbx alone (78% 
[65/83] vs. 63% [52/83], p < 0.005). Moreover, comPbx 
detected more frequently tumour progression to clinical-
ly significant PCa to Gleason score ≥7 (3 + 4) than fusPbx 
(48% [40/83] vs. 39% [32/83], p = 0.008) and sysPbx alone 
(48% [40/83] vs. 37% [31/83], p = 0.012). Reclassification 
according to PRIAS occurred more frequently in comPbx 
than in each modality alone (72% in comPbx vs. 64% in 
fusPbx [p = 0.016] and vs. 59% in sysPbx [p = 0.001]).
Detection and Reclassification Rates in Patients 
with Initial MRI/Ultrasound-Fusion Biopsy in 
Combination with Systematic Biopsy
Furthermore, we investigated patients with low-risk 
PCa who were diagnosed by initial fusPbx in combination 
with sysPbx (n = 14). Six out of 14 (43%) of these patients 
showed tumour progression to a GS ≥7 (3 + 4) and 52% 
(8/14) were reclassified according to PRIAS. Patients with 
fusPbx did not show a lower rate of tumour progression 
than patients with solely sysPbx in surveillance biopsy 
(both 28%). Table 3 described changes in mpMRI and 
evidence of clinical and histopathological progression at 
the time of surveillance biopsy compared to initial biopsy. 
Three patients with tumour progression presented pro-
gression in mpMRI (size or grade of suspicion) performed 
before surveillance biopsy.
Detection Rate in Lesions Detected by mpMRI
In total, 153 lesions were detected. If lesions were not 
classified according to PI-RADS initially, PI-RADS was 
not used later in the re-evaluation by the in-house radi-
ologist. In 31 patients, mpMRI was not evaluated accord-
ing to PI-RADS due to missed initial classification in am-
bulatory radiology offices or missed sequences impeding 
the application of PI-RADS. So, PI-RADS was applied in 
52 patients. Thus, 39 lesions (26%) were not investigated 
according to PI-RADS. One hundred fourteen lesions 
were evaluated according to PI-RADS (PI-RADS 2: n = 
21, PI-RADS 3: n = 37, PI-RADS 4: n = 33, PI-RADS 5: 
n = 23). PCa with a GS ≥7 (3 + 4) was detected in 19% (n = 
4), 21% (n = 8), 18% (n = 6) and 57% (n = 13) in lesions 
classified as PI-RADS 2, 3, 4, and 5, respectively.
Regarding the maxPI-RADS presented by the lesion with 
the highest PI-RADS per patient (n = 52), 8% (n = 4), 38% 
(n = 20), 29% (n = 15) and 25% (n = 13) patients presented a 
maxPI-RADS of 2, 3, 4, and 5, respectively. Figure 1 repre-
sents the overall cancer detection rate and the detected GS 
in patients with indicated maxPI-RADS in fusPbx and sys-
Pbx and in the combination of both. Regarding the localiza-
tion of lesions harbouring PCa (n = 61), 46% (n = 28), 28% 
(n = 17) and 26% (n = 16) were located in the peripheral, 
central and anterior zone of the prostate respectively. 
Table 2. Biopsy-proven prostate cancer with Gleason score (GS) in MRI/ultrasound-fusion biopsy (fusPbx; n = 46) and systematic bi-
opsy (sysPbx; n = 72); dark-grey – concordance, red – clinically significant upgrading, light-grey – insignificant upgrading or change in 
GS
sysPbx
no tumour GS 6 GS 3 + 4 = 7 GS 4 + 3 = 7 GS ≥8
fusPbx
No tumour 18 12 3 2 2
GS 6 6 5 1 2 0
GS 3 + 4 = 7 5 3 10 3 1
GS 4 + 3 = 7 1 0 2 1 2
GS ≥8 1 0 0 2 1
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In uni- and multivariate analyses for the prediction of 
reclassification according to PRIAS criteria in surveil-
lance biopsy, the strongest independent predictor was a 
high PSA-density defined as a ≥median of 0.12 ng/mL2 
(OR 4.7 95% CI 1.282–16.89; p = 0.019) adjusted to the 
age, median PSA-level, median prostate volume, result of 
the digital rectal examination and evidence of PI-RADS 
≥3 and ≥4 lesions. However, the presence of at least one 
lesion with PI-RADS ≥4 did not predict tumour progres-
sion (OR 1.0, 95% CI 0.336–2.976; p = 1.0) in univariate 
analysis. 
Comparison of Tumour Grading in Biopsy and 
Radical Prostatectomy Specimen in Patients 
Undergoing Radical Prostatectomy
Twenty-nine out of 59 (49%) patients reclassified ac-
cording to PRIAS criteria underwent radical prostatecto-
my at our institution. Histopathological data of the pros-
tatectomy specimen is depicted in Table 4. Eight out of 29 
(28%) of these patients presented an unfavourable tumour 
stage defined as ≥pT3 and one patient (3%) presented 
lymph node metastasis, which was not detected in  mpMRI. 
At staging, no patient presented distant metastasis. 
Table 3. Description of changes mpMRI in patients with initial combination of fusPbx and sysPbx before initialization of active surveil-
lance and outcome in surveillance biopsy
Number of 
patients
Initial MRI MRI at time of  
surveillance biopsy
Criteria for progression Progression in 
Gleason score
Reclassification 
according to PRIAS
number of 
lesions
PI-RADS 
max
number of 
lesions
PI-RADS 
max
PI-RADS size/number 
of lesion
1 3 2 3 3 – – 0 1
2 1 3 1 3 – – 0 0
3 2 3 2 3 – – 1 1
4 2 4 2 4 Yes – 0 1
5 2 5 1 4 Yes Yes 1 1
6 1 3 1 3 – – 1 1
7 2 4 2 4 – – 0 0
8 2 5 4 5 – Yes 1 1
9 1 2 1 2 – – 1 1
10 1 – 2 – – Yes 0 0
11 1 2 1 3 Yes – 1 1
12 4 – 4 4 – – 0 0
13 1 3 1 3 – – 0 0
14 1 4 1 – – – 0 0
0
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Fig. 1. Association between the detection of 
clinically insignificant and significant 
prostate cancer according to PRIAS and 
the maximal PI-RADS in patients with 
mpMRI with indicated PI-RADS (n = 52; 
maxPI-RADS 2: n = 4; maxPI-RADS 3: n = 
20; maxPI-RADS 4: n = 15; maxPI-RADS 
5: n = 13).
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Discussion
In clinical practice, the follow-up for patients under 
AS is based on PSA-value, PSA-density, DRE and re-
peated biopsy in defined intervals according to the 
used AS protocol [13, 14, 19]. However, there is no 
consensus for AS protocols and time points of 
 investigations including surveillance biopsies. More-
over, the definition of clinically significant PCa and 
 tumour progression for AS patients is still heteroge-
neous [2].
MpMRI and consecutive targeted biopsy have shown 
a good accuracy in diagnosing clinically significant PCa 
[11, 20, 21]. Furthermore, mpMRI detects tumour-suspi-
cious lesions with a high sensitivity [5, 8]. Additionally, 
tumour upgrading may be expressed by the progression 
of a tumour-suspicious lesion in terms of the size and 
grade of suspiciousness [22, 23].
In this study, we investigated patients with low-risk PCa 
undergoing surveillance biopsies. To the best of our knowl-
edge, this is the first study comparing transperineal fusPbx 
to conventional transrectal sysPbx as surveillance biopsy in 
patients with low-risk PCa and to provide data of final his-
topathology in radical prostatectomy specimens.
Here, we show that the detection rate of tumour pro-
gression defined as upgrading to a GS ≥7 (3 + 4) tumour 
in fusPbx is as high as in sysPbx. In our study, the combi-
nation of both biopsy modalities outperformed each sin-
gle modality regarding the detection of GS ≥7 (3 + 4; 48 
vs. 39% in fusPbx, p = 0.008 and vs. 37% in sysPbx, p = 
0.0012) and reclassification according to PRIAS (72 vs. 
64% in fusPbx, p = 0.016 and vs. 59% in sysPbx, p = 0.001). 
The median number of taken cores in our cohort was 18 
in comPbx, 12 in sysPbx and 6 in fusPbx. Other study 
groups perform fusPbx in combination with volume-
based systematic template biopsy, which results in a me-
dian number of 20–30 systematic cores, while the detec-
tion rate of all and significant PCa was comparable to our 
detection rates in sysPbx [24–26].
Our reclassification rates according to Gleason score 
and to PRIAS in fusPbx and in the combination with 
sysPbx appear to be high compared to reported reclas-
sification rates of 17–48% for mpMRI and targeted bi-
opsy in the current literature [6, 11, 20, 27–29]. How-
ever, the use of different software systems for fusion bi-
opsies and the heterogeneous definitions for tumour 
upgrading and reclassification might lead to this vari-
ability. Radtke et al. [11] showed that an initial fusPbx in 
combination with sysPbx leads to a significantly less fre-
quent reclassification in surveillance biopsy performed 
by fusPbx in combination with template biopsy than sys-
Pbx alone in the initial biopsy. Moreover, we showed 
that reclassified patients undergoing radical prostatec-
tomy present an unfavourable tumour stage (≥pT3) in 
28%, which is comparable to the current literature [3]. 
Both aspects might indicate that misclassification might 
occur at initial biopsy mainly performed solely by sysPbx 
in our cohort.
In our study, both biopsy modalities alone would miss 
a considerable number of significant PCa detected by the 
other modality (23% in fusPbx vs. 25% in sysPbx). This 
missing rate of significant PCa is comparable to published 
missing rates of up to 30% for fusPbx in confirmatory bi-
opsy and therefore, sysPbx should not be completely re-
placed by exclusive fusPbx [28, 30]. Tran et al. [31] inves-
tigated 207 patients undergoing surveillance biopsy with 
fusPbx in combination with sysPbx. Here, 40% of patients 
presented a tumour upgrading, whereby 24% of them 
were detected on sysPbx, 14% on fusPbx and 2% on both. 
However, they showed that in patients with a negative 
mpMRI, sysPbx still resulted in a 9% upgrading to Glea-
son score ≥4 + 3 and concluded that sysPbx should still 
be offered even with prior extended sextant biopsy [31]. 
Other data confirm this by showing a low relative sensi-
tivity ratio of 0.33 for the detection of Gleason score ≥7 
PCa in mpMRI compared to sysPbx [32]. In contrast, oth-
er study groups demonstrated that mpMRI and targeted 
biopsy mainly contributed to the Gleason score upgrad-
ing, whereas sysPbx did not lead to an upgrading [33]. In 
Table 4. Histopathological data of patients with reclassification ac-
cording to PRIAS criteria who underwent radical prostatectomy a 
tour institution (n = 29)
n %
pT-stage
pT2a 1 3
pT2b 20 69
pT3a 6 21
pT3b 2 7
pN
pN0 28 97
pN1 1 3
Gleason score
6 2 7
3 + 4 18 62
4 + 3 8 28
≥8 1 3
Not described due to neoadjuvant
androgen deprivation therapy 3 10
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our cohort, the combination of both biopsy modalities 
detected a higher rate of upgrading (48%) and reclassifi-
cation to clinically significant PCa (72%) compared both 
modalities alone.
The suspicion grade of lesions detected on mpMRI is 
associated with the detection rate of clinically significant 
PCa. In this study, we demonstrated that higher the PI-
RADS, higher will be the detection rate of clinically sig-
nificant PCa. However, in this cohort, the detection rate 
of clinically significant PCa in lesions classified as PI-
RADS 2 by fusPbx is high. As we have shown in a previous 
study, detection rates of clinically significant PCa in PI-
RADS 2 or PI-RADS 3 lesions is higher in patients under-
going surveillance biopsy within an AS protocol than in 
patients undergoing first or repeat biopsy [34]. In patients 
on AS, higher detection rates of clinically significant PCa 
in low-suspicious lesions might be related to a higher evi-
dence of PCa [34]. Furthermore, in the present study, we 
found a relatively high detection rate of clinically signifi-
cant PCa in comPbx in patients presenting a maxPI-
RADS 3 compared to patients presenting a maxPI-RADS 
4–5. This might be related to a high detection rate of clin-
ically significant in sysPbx. Nassiri et al. [23] reported sur-
veillance biopsy outcomes in patients with initial and sur-
veillance fusPbx and showed a high rate of Gleason score 
upgrading of 97% in mpMRI-lesions progressing in size 
or grade of suspiciousness. Furthermore, it has been dem-
onstrated that stable findings on mpMRI were associated 
by stable tumour grading in surveillance biopsy [35, 36]. 
Moreover, highly suspicious lesions detected in mpMRI 
were the most significant predictor of Gleason score up-
grading [37]. In accordance with these data, Hu et al. [22] 
described a likelihood of reclassification of 24–29% in 
low-suspicious lesions, whereas the reclassification rate 
was 45 to 100% in highly suspicious lesions. Our data un-
derline these findings, since in 50% of those presenting 
tumour progression to GS ≥7 (3 + 4) or reclassification in 
our cohort also showed progression of lesions detected in 
mpMRI (Table 3). However, we investigated only a small 
number of patients in this subgroup with initial fusion bi-
opsy in the current study. Additionally, the localization of 
lesions in mpMRI may contribute to tumour upgrading 
and consecutive reclassification. So, in our cohort, 26% of 
lesions harbouring significant PCa with a GS ≥7 (3 + 4) 
were located in the anterior zone of the prostate, which is 
not easily reached by sysPbx. 
Additionally, it has been reported that the combination 
of findings in mpMRI and clinical parameter like PSA den-
sity [38] and the use of nomograms based on these param-
eter might help to predict tumour upgrading to clinically 
significant PCa in a non-invasive approach to confirm AS 
[7, 29, 39]. However, this approach has to be investigated 
continuously especially with regard to further diagnostic 
and predictive biomarkers. So far, in the synopsis of our re-
sults and in the context of the current literature, mpMRI and 
consecutive targeted biopsy should be still combined with 
sysPbx to avoid missing the tumour progression and reclas-
sification in patients under AS. However, according to avail-
able data, decisions related to whether a surveillance biopsy 
can be omitted at all cannot be based on MRI findings alone.
Our study has several limitations. First, we investigated 
a rather small number of patients with low-risk PCa un-
dergoing surveillance biopsy. Therefore, the difference in 
the detection rates in fusPbx compared to sysPbx might be 
higher with a higher number of included patients. Second, 
initial biopsy was not performed in all patients with solely 
sysPbx. In initial biopsy, 17% of patients underwent fus-
Pbx combined with sysPbx. This heterogeneous patient 
cohort might lead to an overestimation of the accuracy in 
initial biopsy. However, in this cohort, this subgroup with 
initial fusion biopsy did not show a lower rate of reclassi-
fication.
Third, we did not acquire data about further treatment 
in all patients with proven tumour progression, so that 
our results of final histopathology gained by radical pros-
tatectomy should be interpreted with caution. 
Next, fusPbx and sysPbx were performed subsequent-
ly by the same urologist and hence he was unblinded. Sys-
tematic cores were placed according to a pre-defined 
scheme. There was no additional software-based docu-
mentation that would allow the retrospective analysis of 
systematic cores. Consequently, the knowledge about the 
location of lesions in mpMRI could have influenced the 
operator in needle placement unwittingly during sysPbx. 
This could have resulted in a falsely high detection rate in 
sysPbx. Another limitation is that PI-RADS was not ap-
plied in all patients. However, detection rates of any and 
clinically significant cancer in the subgroup analysis in-
cluding only patients with reported PI-RADS showed 
similar results compared to the whole cohort. Finally, we 
did not perform a standardized long-term follow-up as-
sessment to detect false-negative cases.
Conclusions
The combination of fusPbx and sysPbx outperforms 
both modalities alone with regard to the detection of tu-
mour upgrading and reclassification in patients with low-
risk PCa under AS. 
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Thus, mpMRI and targeted fusPbx in combination 
with sysPbx should be offered to patients undergoing 
control-biopsy for low-risk PCa in an AS protocol. How-
ever, due to a still high missing rate of significant PCa in 
fusPbx alone, sysPbx should not be omitted at this point. 
Finally, according to our data, control biopsies during AS 
cannot be replaced by MRI alone.
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